readthroughSign in
Nov 13, 2026Regulatory milestone

CHMP backs single Bexsero booster dose for ages 10 and up

GSK said the EU committee recommended a one-dose Meningitis B booster using Bexsero for people 10 and older who were vaccinated at least two years earlier.

GSK plc announced on 13 November 2026 that the Committee for Medicinal Products for Human Use of the European Medicines Agency recommended updating the Bexsero label to include a single booster dose for individuals aged 10 years and older who were previously vaccinated at least two years earlier with Bexsero.1

The committee's recommendation rests on findings that immune memory established following primary vaccination in infancy can be boosted with a single dose up to 19 years later.1

The supporting data come from Men-B-096, which GSK described as a Phase IIIb open label, multi-centre study that assessed the immune response and safety of a single booster dose of Bexsero in healthy individuals aged 10-20 years who previously completed their primary vaccination series with Bexsero.1 The company said the study met its primary endpoint, and the safety and reactogenicity of a single booster dose is consistent with the known safety profile of Bexsero in this age group.1

According to the filing, the study enrolled 312 participants across Finland, Italy, Spain and the UK, including 234 who had received Bexsero during infancy and 78 who had not previously received a meningococcal B vaccine.1 The primary endpoint compared immune response rates between these two groups, with GSK stating the primary endpoint was to assess the superiority of the immune response to a single booster dose in previously vaccinated participants compared with a first dose in adolescents who hadn't received a MenB vaccine in the past.1

GSK noted that Bexsero is registered in 61 countries for the prevention of Invasive Meningococcal Disease caused by Neisseria meningitidis serogroup B,1 and that in Europe, it is included in 15 national and/or regional immunisation programmes for infants, and 3 national immunisation programmes for adolescents.1 The company also said around 140 million doses of Bexsero have been distributed globally since 2015.1

Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.